Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa

British Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2009, Pages 50-60

  Ekhart, Corine ^a   Doodeman, Valerie D ^a   Rodenhuis, Sjoerd ^b   Smits, Paul H M ^a   Beijnen, Jos H ^a,c   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Pharmacogenetics; Population pharmacokinetics; Tepa; Thiotepa

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GENOMIC DNA; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE P1; TEPA; THIOTEPA;

ADOLESCENT; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CYP2B6 GENE; CYP3A4 GENE; CYP3A5 GENE; DNA SEQUENCE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GAS CHROMATOGRAPHY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GSTA1 GENE; GSTP1 GENE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEOPLASM; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CARBOPLATIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; THIOTEPA; TRIETHYLENEPHOSPHORAMIDE;

EID: 58149117630     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03321.x     Document Type: Article

References (50)

1. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003 348 : 538 49.
2. Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992 3 : 855 60.
3. Miller B, Tenenholz T, Egorin MJ, Sosnovsky G, Rao NU, Gutierrez PL. Cellular pharmacology of N,N′,N″-triethylene thiophosphoramide. Cancer Lett 1988 41 : 157 68.
4. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M. Dosing of thioTEPA for myeloablative therapy. Cancer Chemother Pharmacol 1995 37 : 155 60.
5. Huitema ADR, Smits KD, Mathot RA, Schellens JH, Rodenhuis S, Beijnen JH. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs 2000 11 : 515 33.
6. Huitema ADR, Spaander M, Mathot RAA, Tibben MM, Holtkamp MJ, Beijnen JH. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 2002 13 : 374 84.
7. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002 49 : 461 7.
8. Dirven HA, Dictus EL, Broeders NL, van Ommen B, Van Bladeren PJ. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res 1995 55 : 1701 6.
9. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006 25 : 1679 91.
10. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003 42 : 299 305.
11. Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006 16 : 59 71.
12. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 91.
13. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999 366 : 89 94.
14. de Jonge ME, Huitema ADR, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005 11 : 273 83.
15. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003 349 : 7 16.
16. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach IC, Schornagel JH. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996 14 : 1473 83.
17. de Jonge ME, van Dam SM, Hillebrand MJ, Rosing H, Huitema ADR, Rodenhuis S. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N″-triethylenethiophosphoramide (thiotepa) and N,N′,N″-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004 39 : 262 71.
18. Huitema ADR, Tibben MM, Kerbusch T, Zwikker JW, Rodenhuis S, Beijnen JH. Simultaneous determination of N,N′,N″-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl 1998 716 : 177 86.
19. FDA. FDA guidelines. Available at http://www.fda.gov/cder/guidance/ 4252fnl.htm (last accessed 21 February 2008).
20. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990 28 : 495 503.
21. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001 11 : 399 415.
22. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 67 : 48 56.
23. van Schaik RH, van der Heiden I, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002 48 : 1668 71.
24. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001 11 : 663 9.
25. Jeronimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002 11 : 445 50.
26. Wang Y, Spitz MR, Schabath MB, Ali-Osman F, Mata H, Wu X. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer 2003 40 : 25 32.
27. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn 2004 31 : 135 56.
28. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. The CYP3A4*3 allele: is it really rare? Clin Chem 2001 47 : 1104 6.
29. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000 60 : 5621 4.
30. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003 103 : 810 4.
31. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003 102 : 2345 50.
32. Huitema ADR, Mathot RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br J Clin Pharmacol 2001 51 : 61 70.
33. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003 31 : 398 403.
34. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 2001 281 : 1256 60.
35. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002 30 : 1108 14.
36. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004 5 : 243 72.
37. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 11 : 447 58.
38. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000 68 : 82 91.
39. Min DI, Ellingrod VL. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003 25 : 305 9.
40. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004 76 : 545 56.
41. He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005 77 : 373 87.
42. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002 12 : 355 66.
43. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001 11 : 773 9.
44. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003 13 : 461 72.
45. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004 4 : 34 9.
46. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002 30 : 1491 6.
47. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005 11 : 8097 104.
48. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006 368 : 93 8.
49. Bredschneider M, Klein K, Murdter TE, Marx C, Eichelbaum M, Nussler AK. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 2002 71 : 479 87.
50. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997 272 : 10004 12.